Naamidine J
Based on 1 Customer Validation
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.41%
- CAS No.: 2227550-73-2
- 화학식: C25H27N5O5
- 분자량:477.51
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
IL-1β |
IL-6 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
4.43 μM
Compound: Naamidine J
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 37040446] |
| HepG2 | IC50 |
0.31 μM
Compound: Naamidine J
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 37040446] |
| K562 | IC50 |
0.62 μM
Compound: Naamidine J
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 37040446] |
| K562 | IC50 |
11.3 μM
Compound: Naamidine J
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37040446] |
| RKO | IC50 |
>40 μM
Compound: Naamidine J
|
Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 37040446] |
Naamidine J (5 μM, 24 h) has cytotoxicity against K562 cells with an IC50 of 11.3 μM but is not toxic to macrophages and RKO cells (IC50 > 40 μM)[1][2].
Naamidine J (10 μM, 24 h) reduces PD-L1 expression in RKO cells and PDAC cells[1][3].
Naamidine J (1-5 μM, 5 h) inhibits the Inflammatory response in LPS (HY-D1056)-induced RAW264.7 macrophages[2].
Naamidine J (5 μM, 5 h) inhibits nuclear translocation of transcription factor SP1 mediated by CSE1L in LPS-induced macrophages[2].
Naamidine J (10 μM, 24 h) restores the cytotoxicity of CD8+ T cells and significantly reduce the survival of PDAC cells (MIA-PaCa2, BxPC-3)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RKO cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Had a certain inhibitory effect on PD-L1 expression.
-
Cell Line:RAW264.7 cells
-
Concentration:1, 2 and 5 μM
-
Incubation Time:Pre-treatment for 3 hours, followed by co-stimulation with LPS for 2 hours
-
Result:Exhibited concentration-dependent inhibition of TNF-α release.
-
Cell Line:RAW264.7 cells
-
Concentration:1, 2 and 5 μM
-
Incubation Time:Pre-treatment for 3 hours, followed by co-stimulation with LPS for 2 hours
-
Result:Inhibited pro-inflammatory factors (TNF-α, IL-1β, IL-6), and promoted anti-inflammatory factors (CD206, Arg-1).
-
Cell Line:RAW264.7 cells
-
Concentration:5 μM
-
Incubation Time:Pre-treatment for 3 hours, followed by co-stimulation with LPS for 2 hours
-
Result:Resulted in the accumulation of SP1 in the cytoplasm.
Enhanced the interaction between CSE1L and SP1.
Naamidine J (30 mg/kg, i.p., once every three days for 28 days) significantly enhances the proportion of CD8+ Tex subset and reduced the proportion of intermediate CD8+ Tex subset in mice bearing subcutaneous tumors with high NAT10 expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute lung injury model established in mice[2]
-
Dosage:10 and 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 3 days
-
Result:Significantly reduced the increase in lung organ coefficient induced by LPS and alleviate pulmonary edema.
Significantly improved the pathological damage of lung tissue and reduce the infiltration of inflammatory cells.
Significantly reduced the protein levels of TNF-α in serum and lung tissue, as well as the mRNA expression of various inflammatory factors.
Reduced the proportion of pro-inflammatory M1-type macrophages in the lung tissue and increased the proportion of anti-inflammatory M2-type macrophages.
-
Animal Model:PanO2 xenograft model established in four-week-old female C57BL/6 mice (18 to 20 g)[3]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once every three days for 28 days
-
Result:Significantly inhibited tumor growth in the Nat10-OE group.
Reversed T cell exhaustion and restores anti-tumor function.
Increased the infiltration of CD8+ T cells, reduced the PD-1 with IFNγ and exhausted phenotype, and increased the PD-1-IFNγ+ cytotoxic phenotype.
Chemical Information
-
CAS No. 2227550-73-2
-
Appearance Solid
-
분자량 477.51
-
화학식 C25H27N5O5
-
Color Off-white to light yellow
-
SMILES
O=C1N=C(C(N1C)=O)NC2=NC(CC3=CC=C(C=C3)OC)=C(CC4=CC=C(C(OC)=C4)OC)N2C
-
Structure Classification
-
Initial Source
Pericharax heteroraphis
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
용액&용해도
DMSO : 4.55 mg/mL (9.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fu PP, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66(8):5427-5438. [Content Brief]
[2]. Gao CL, et al. Chemoproteomics of Marine Natural Product Naamidine J Unveils CSE1L as a Therapeutic Target in Acute Lung Injury. J Am Chem Soc. 2024 Oct 16;146(41):28384-28397. [Content Brief]
[3]. Chen E, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Cancer Commun (Lond). 2025 Sep;45(9):1162-1187. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0942 mL | 10.4710 mL | 20.9420 mL | 52.3549 mL |
| 5 mM | 0.4188 mL | 2.0942 mL | 4.1884 mL | 10.4710 mL |
Naamidine J Related Classifications
HY-N14001 Related Classifications
Powered by Bioz